APHA
The Post Roll: Earnings – Aphria, Organigram, Aurora & Valens
In this edition of The Post Roll, Thomas George and Scott Willis review the flurry of earnings releases in the…
Aphria Demonstrates Early Cannabis 2.0 Success with Q3 Revenue Beat
Canadian licensed producer Aphria (NYSE:APHA, TSE:APHA) announced a surprise beat today with revenue of C$144 million beating consensus by a…
The Post-Roll: Bull Market for Vice (Booze, Smokes and Pot)
https://www.youtube.com/watch?v=Mg6DcM_e04g In this weeks episode, we're talking about vice stocks. With much of the global population stuck indoors,…
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Jan 25th, 2020)
MedMen Confirms Rumours, in The Middle of a 'Non-Bankruptcy' Bottom Line: Last weekend we reported on rumours that MedMen was…
Aphria Receives Market Stamp of Approval With New $100 Million Investment
Today it was announced that cannabis producer Aphria (TSE:APHA; NYSE:APHA) received a new C$100 million investment from one large institutional…
Aphria Receives EU GMP Certification as the Company Eyes Expansion into Germany
Aphria Inc. (TSE: APHA; NYSE: APHA) has announced that it has received the European Union Goods and Manufacturing Practices (EU…
OGI Smashes Expectations But Actual Results are a House of Cannabis Horrors.
Organigram (NASDAQ: OGI) beat lowered analyst estimates but dig a little deeper and the big stock price spike looks like…
Aphria (APHA) Earnings – Guidance Cut But Still the Best Game in Town
Aphria (TSE: APHA; NYSE: APHA) earnings showed it has the cash to weather the coming storm and the profitability to…
GW Pharmaceuticals Releases a Q4 Revenue Beat, but Will the Rapid Growth Continue?
Bottom Line Cannabinoid prescription medicine company GW Pharmaceuticals (NASDAQ: GWPH) pre-announced revenues for its fourth quarter and full-year last night.…